EMAIL THIS PAGE TO A FRIEND

Cancer immunology research

Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.


PMID 24764578

Abstract

A major barrier to vaccines in cancer treatment is their failure to activate and maintain a complete cancer-specific CD8(+) effector T-cell repertoire. Low-avidity T cells are more likely to escape clonal deletion in the thymus when compared with high-avidity T cells, and therefore comprise the major population of effector T cells available for activation in patients with cancer. However, low-avidity T cells fail to traffic into the tumor microenvironment and function in eradicating tumor under optimal vaccination conditions as opposed to high-avidity T cells that escape clonal deletion and function in tumor killing. We used high- and low-avidity T-cell receptor transgenic CD8(+) T cells specific for the immunodominant epitope HER2/neu (RNEU420-429) to identify signaling pathways responsible for the inferior activity of the low-avidity T cells. Adoptive transfer of these cells into tumor-bearing vaccinated mice identified the members of apoptosis pathways that are upregulated in low-avidity T cells. The increased expression of proapoptotic proteins by low-avidity T cells promoted their own cell death and also that of other tumor-specific CD8(+) T cells within their local environment. Importantly, we show that this proapoptotic effect can be overcome by using a strong costimulatory signal that prevents the activation-induced cell death and enables the low-avidity T cells to traffic into the tumor and assist in tumor clearance. These findings identify new therapeutic opportunities for activating the most potent anticancer T-cell responses.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1412683
ANTI-IFNA1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1410692
Anti-IFNA1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4502982
Anti-TNFA antibody produced in rabbit, affinity isolated antibody
T0813 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T1816 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T0938 Anti-Tumor Necrosis Factor-α antibody produced in goat, affinity isolated antibody, lyophilized powder
T8300
Anti-Tumor Necrosis Factor-α antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1402713
Monoclonal Anti-CD24 antibody produced in mouse, clone 1C4, purified immunoglobulin, buffered aqueous solution
SAB4700623 Monoclonal Anti-CD24 antibody produced in mouse, clone SN3, purified immunoglobulin, buffered aqueous solution
WH0003439M7
Monoclonal Anti-IFNA1 antibody produced in mouse, clone 3C6, purified immunoglobulin, buffered aqueous solution
WH0007124M2
Monoclonal Anti-TNF antibody produced in mouse, clone 1C3-A1-F4, purified immunoglobulin, buffered aqueous solution
SAB1404480
Monoclonal Anti-TNF antibody produced in mouse, clone M1-C4, purified immunoglobulin, buffered aqueous solution
T3198 Monoclonal Anti-Tumor Necrosis Factor-α antibody produced in mouse, clone 45418.111, purified immunoglobulin, lyophilized powder
T6817 Monoclonal Anti-Tumor Necrosis Factor-α antibody produced in mouse, clone 28401, purified immunoglobulin, lyophilized powder